The disclosure features methods for safely and effectively administering exogenous LAL (e.g., sebelipase alfa) to pediatric LAL-D patients, as well as methods to prevent and ameliorate infusion reactions in LAL-D pediatric patients receiving exogenous LAL. In particular, disclosed herein are specific dosages and regimens for administering exogenous LAL to a pediatric patient having LAL-D, such dosages and regimens being designed to increase a patient's tolerance of the therapeutic, decrease the likelihood of (e.g., desensitize against) an infusion-related reaction, and maximize the amount of dose that may be administered to the patient safely, so as to safely achieve maximum therapeutic benefits.
展开▼
